Garen G. Bohlin
CIK: 0001254705
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- May 21, 2026KPTI
Karyopharm Therapeutics Inc.
Award(A)Direct15.5K shares- - May 14, 2026COLL
COLLEGIUM PHARMACEUTICAL, INC
Award(A)Direct8.7K shares- - May 11, 2026COLL
COLLEGIUM PHARMACEUTICAL, INC
Exercise(M)Direct8.7K shares at avg. $16.49$143K - May 11, 2026COLL
COLLEGIUM PHARMACEUTICAL, INC
Sale(S)Direct8.7K shares at avg. $37.18$323K - May 28, 2025KPTI
Karyopharm Therapeutics Inc.
Award(A)DirectNonstatutory Stock Option (right to buy)
4.6K shares- - May 15, 2025COLL
COLLEGIUM PHARMACEUTICAL, INC
Award(A)Direct9.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 21, 2026 |  KPTI Karyopharm Therapeutics Inc. | Award(A) | 15,508 | - | $0 | Direct |
| May 14, 2026 |  COLL COLLEGIUM PHARMACEUTICAL, INC | Award(A) | 8,741 | - | $0 | Direct |
| May 11, 2026 | COLL COLLEGIUM PHARMACEUTICAL, INC | Exercise(M) | 8,700 | $16.49 | $143,463 | Direct |
| May 11, 2026 | COLL COLLEGIUM PHARMACEUTICAL, INC | Sale(S) | 8,700 | $37.18 | $323,491 | Direct |
| May 28, 2025 | KPTI Karyopharm Therapeutics Inc. | Award(A) Nonstatutory Stock Option (right to buy) | 4,600 | - | - | Direct |
| May 15, 2025 | COLL COLLEGIUM PHARMACEUTICAL, INC | Award(A) | 9,791 | - | - | Direct |
1-6 of 6 transactions
About BOHLIN GAREN G
BOHLIN GAREN G (SEC CIK 0001254705) files insider reports with the SEC as Director of Karyopharm Therapeutics Inc. (KPTI) and Director of COLLEGIUM PHARMACEUTICAL, INC (COLL).
Signal8 holds 5 ownership filings by BOHLIN GAREN G, all Form 4s, filed between May 19, 2025 and May 26, 2026. Those filings report 6 transactions, from May 15, 2025 to May 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on BOHLIN GAREN G's filings is in STOUGHTON, MA.
Recent filings by BOHLIN GAREN G
- May 21, 2026: Grant or award of KPTI shares (Form 4, code A).
- May 14, 2026: Grant or award of COLL shares (Form 4, code A).
- May 11, 2026: Option exercise of COLL shares (Form 4, code M).
- May 11, 2026: Open-market sale of COLL shares (Form 4, code S).
- May 28, 2025: Grant or award of KPTI derivative securities (Form 4, code A).
Other insiders filing for Karyopharm Therapeutics Inc. (KPTI)
- Abate Kristin, Chief Accounting Officer
- Poulton Stuart, EVP, Chief Development Officer
- Oliger Christy J., Director
- PAKIANATHAN DEEPIKA, Director
- Schor Chen, Director
- Su Zhen, Director